MASTERPLAN

1. 18:59
   ESMO 2026 现场信号

   #ESMO26 Day 1 highlight for me: MASTERPLAN, now in Lancet Oncology.
2. 06:00
   ESMO 2026 现场信号

   📣#NewPublication: Results from the #MASTERPLAN randomised phase 2 trial have been presented at #ESMO26 and published in @TheLancetOncol.
3. 05:41
   ESMO 2026 现场信号

   Nice to see the MASTERPLAN study presented #ESMO26 and published in @TheLancetOncol !
4. 00:32
   ESMO 2026 现场信号

   Big result from @_ShankarSiva and the MASTERPLAN team. The detail for fellows: this is a randomized phase 2 whose primary endpoint was 12-month locoregional recurrence, so the surv
5. 00:00
   The Lancet Oncology

   MASTERPLAN二期随机试验显示，围手术期化疗联合SBRT减少高危局部分期PDAC局部区域复发且未显著增加毒性

   Australasian Gastro-Intestinal Trials Group（AGITG）开展的MASTERPLAN开放标签二期多中心随机试验显示，围手术期化疗联合SBRT显著降低高危局部分期PDAC的局部区域复发。与单纯围手术期化疗相比，联合SBRT未显著增加毒性；作者认为该策略值得在更大规模研究中进一步考察。

1. 23:37
   ESMO 2026 现场信号

   MASTERPLAN randomised ph2
2. 23:27
   ESMO 2026 现场信号

   AGITG MASTERPLAN ph II study: mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced PDAC
3. 23:27
   ESMO 2026 现场信号

   🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs
4. 19:05
   ESMO 2026 现场信号

   MASTERPLAN (#ESMO26 , n=74): SBRT + chemotherapy vs chemotherapy alone:
5. 07:03
   ESMO 2026 现场信号

   Encouraging pancreas SBRT data from MASTERPLAN. Adding 40 Gy/5 fx cut 12mo locoregional recurrence from 52% to 20% (P=.022).
6. 05:55
   ESMO 2026 现场信号

   🔥AGITG MASTERPLAN🔥

当前热度 41·可比范围峰值 77（10月24日 07:00）·近 24 小时可比范围变化 -41%·当前参与者 11

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。